Effects of the orexin receptor 2 agonist danavorexton on emergence from general anaesthesia and opioid-induced sedation, respiratory depression, and analgesia in rats and monkeys
British Journal of Anaesthesia · 2024-03 · 132 (3) · 541-552
DOI: 10.1016/j.bja.2023.12.032 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Anaesthesia, 2024-03. Verfasst von Motohisa Suzuki und 3 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan. Hauptthemen laut MEDLINE: Propofol, Isoflurane, Respiratory Insufficiency, Analgesia. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Takeda Pharmaceutical Company Limited.
Themen: Depression
Abstract (Originalsprache)
BACKGROUND: Delayed emergence from general anaesthesia, opioid-induced sedation, and opioid-induced respiratory depression is associated with perioperative complications. We characterised the preclinical effects of the orexin receptor 2 (OX2R)-selective agonist danavorexton (TAK-925) on emergence from anaesthesia and reversal of fentanyl-induced sedation, respiratory depression, and analgesia. METHODS: Emergence from isoflurane- or propofol-induced anaesthesia and fentanyl-induced sedation were investigated by righting reflex, rotarod, and electroencephalography in rats or monkeys. Fentanyl-induced respiratory depression was assessed by arterial blood gas analysis and whole-body plethysmography in rats and monkeys. Analgesia was evaluated using formalin- and skin incision-induced pain models in rats. RESULTS: Danavorexton shortened emergence from isoflurane- or propofol-induced anaesthesia and from fentanyl-induced sedation at 1 (P=0.005), 3 (P=0.006), and 3 mg kg-1 s.c. (P=0.022), respectively, by righting reflex in rats. Danavorexton (10 mg kg-1 s.c.) accelerated recovery from isoflurane-, propofol- and fentanyl-induced motor impairment in separate rotarod tests in rats (P=0.008, P=0.007, P=0.017, respectively), and reversed anaesthesia and fentanyl-induced delta-power increases. Danavorexton shortened emergence (return of righting reflex) from isoflurane- or propofol-induced anaesthesia at 1 (P=0.002) and 3 mg kg-1 (P=0.004), respectively, in cynomolgus monkeys. Danavorexton (10 mg kg-1 s.c.) reversed fentanyl-induced increase in Pco2 (P=0.006), and decrease in Po2 (P=0.015) and pH (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
- Neuroscience Therapeutic Area Unit, Takeda Development Centre Americas, Inc., Cambridge, MA, USA.
- Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan. Electronic address: haruhide.kimura@takeda.com.
Förderung
- Takeda Pharmaceutical Company Limited
Zitieren
APA
Suzuki, M., Shiraishi, E., Cronican, J., & Kimura, H. (2024). Effects of the orexin receptor 2 agonist danavorexton on emergence from general anaesthesia and opioid-induced sedation, respiratory depression, and analgesia in rats and monkeys. British Journal of Anaesthesia, 132(3), 541-552. https://doi.org/10.1016/j.bja.2023.12.032
Vancouver
Suzuki M, Shiraishi E, Cronican J, Kimura H. Effects of the orexin receptor 2 agonist danavorexton on emergence from general anaesthesia and opioid-induced sedation, respiratory depression, and analgesia in rats and monkeys. British Journal of Anaesthesia. 2024;132(3):541-552. doi:10.1016/j.bja.2023.12.032
BibTeX
@article{Suzuki2024,
author = {Suzuki, Motohisa and Shiraishi, Eri and Cronican, James and Kimura, Haruhide},
title = {Effects of the orexin receptor 2 agonist danavorexton on emergence from general anaesthesia and opioid-induced sedation, respiratory depression, and analgesia in rats and monkeys},
journal = {British Journal of Anaesthesia},
year = {2024},
volume = {132},
number = {3},
pages = {541--552},
doi = {10.1016/j.bja.2023.12.032}
}
EUVIMED